A 14-week, Randomized, Double-Blinded, Placebo-Controlled Monotherapy Trial of Pregabalin in Patients With Fibromyalgia

Journal of Pain

Volumn 9, Issue 9, 2008, Pages 792-805

  Arnold, Lesley M ^a   Russell, I Jon ^b   Diri, E W ^c   Duan, W Rachel ^d   Young Jr , James P ^d   Sharma, Uma ^e   Martin, Susan A ^d   Barrett, Jeannette A ^f   Haig, George ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Trinity Health   (United States)

^d PFIZER INC   (United States)

^e MMS HOLDINGS INC   (United States)

^f Pfizer Global Pharmaceuticals   (United States)

Author keywords

controlled trial; fibromyalgia; Pregabalin; randomized

Indexed keywords

PLACEBO; PREGABALIN;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP; SOMNOLENCE;

ADULT; ANALGESICS; ANALYSIS OF VARIANCE; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PLACEBOS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 49649095341     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2008.03.013     Document Type: Article

References (36)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision (2000), American Psychiatric Association, Washington, DC
2. Arnold L.M. Biology and therapy of fibromyalgia: New therapies in fibromyalgia. Arthritis Res Ther 8 (2006) 212
3. Arnold L.M., Hudson J.I., Keck Jr. P.E., Auchenbach M.B., Javaras K.N., and Hess E.V. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 67 (2006) 1219-1225
4. Baranauskas G., and Nistri A. Sensitization of pain pathways in the spinal cord: Cellular mechanisms. Prog Neurobiol 54 (1998) 349-365
5. Belza B., Henke C., Yelin E., Epstein W.V., and Gilless C.L. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 42 (1993) 93-99
6. Bennett R.M. Emerging concepts in the neurobiology of chronic pain: Evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 74 (1999) 385-398
7. In: Berry D. (Ed). Statistical Methodology in the Pharmaceutical Sciences (1990), Marcel Dekker, New York, NY 403-408
8. Burckhardt C.S., Clark S.R., and Bennett R.M. The Fibromyalgia Impact Questionnaire (FIQ): Development and validation. J Rheumatol 18 (1991) 728-733
9. Clauw D.J., and Crofford L.J. Chronic widespread pain and fibromyalgia: What we know, and what we need to know. Best Pract Res Clin Rheumatol 17 (2003) 685-701
10. Crofford L.J., Rowbotham M.C., Mease P.J., Russell I.J., Dworkin R.H., Corbin A.E., Young Jr. J.P., LaMoreaux L.K., Martin S.A., Sharma U., and Pregabalin 1008-1-5 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
11. 2δ ligands: Novel modulators of neurotransmission. Trends Pharmacol Sci 28 (2007) 75-82
12. Evans C.J., Parthan A., and Le K. Economic and humanistic burden of fibromyalgia in the USA. Exp Rev Pharmacoeconomics Outcomes Res 6 (2006) 303-314
13. Farrar J.T., Young Jr. J.P., LaMoreaux L., Werth J.L., and Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2001) 149-158
14. 2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. PNAS 103 (2006) 17537-17542
15. Gracely R.H., Petzke F., Wolf J.M., and Clauw D.J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46 (2002) 1333-1343
16. Hays R.D., and Stewart A.L. Sleep measures. In: Stewart A.L., and Ware Jr. J.E. (Eds). Measuring Functioning and Well-Being (1992), Duke University Press, Durham, NC 235-239
17. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988) 800-802
18. Hoffman D.L., and Dukes E.M. The health status burden of people with fibromyalgia: A review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 62 (2008) 115-126
19. Huson L.W., Chung J., and Salgo M. Missing data imputation in two phase III trials treating HIV1 infection. J Biopharm Stat 17 (2007) 159-172
20. Jensen M.P., and Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk D.C., and Melzack R. (Eds). Handbook of Pain Assessment (1992), The Guildford Press, New York, NY 135-151
21. Lesser H., Sharma U., LaMoreaux L., and Poole R.M. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 63 (2004) 2104-2110
22. Littell R.C., Milliken G.A., Stroup W.W., and Wolfinger R.D. SAS System for Mixed Models (1996), SAS Institute, Inc, Cary, NC
23. Max M.B. Neuropathic pain syndromes. In: Max M., Portenoy R., and Laska E. (Eds). Advances in Pain Research and Therapy (1991), Raven Press Ltd, New York, NY 193-219
24. Mease P.J. Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 75 (2005) 6-21
25. Moldofsky H. Management of sleep disorders in fibromyalgia. Rheum Dis Clin North Am 28 (2002) 353-365
26. Pfizer Inc: Lyrica (pregabalin), package insert. New York, NY; June 2007
27. Salaffi F., Stancati A., Silvestri C.A., Ciapetti A., and Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 8 (2004) 283-291
28. SAS Institute, Inc. SAS/STAT Users' Guide. 4th Edition. Version 6 (1989), SAS Institute, Inc, Cary, NC
29. Staud R., and Rodriguez M.E. Mechanisms of disease: Pain in fibromyalgia syndrome. Nat Clin Pract 2 (2006) 90-98
30. 2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73 (2007) 137-150
31. Ware J.E., Kosinski M., and Dewey J.E. How to Score Version 2 of the SF-36 (r) Health Survey (2000), Quality Metric Incorporated, Lincoln, RI
32. Watson C.P.N. Neuropathic pain syndromes. In: Max M., Portenoy R., and Laska E. (Eds). Advances in Pain Research and Therapy (1991), Raven Press Ltd, New York 221-231
33. Wolfe F., Ross K., Anderson J., Russell I.J., and Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38 (1995) 19-28
34. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., and Clark P. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum 33 (1990) 160-172
35. Woolf C.J. Moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140 (2004) 441-451
36. Zigmond A., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983) 361-370